[go: up one dir, main page]

WO2011107922A3 - Extended release composition of milnacipran - Google Patents

Extended release composition of milnacipran Download PDF

Info

Publication number
WO2011107922A3
WO2011107922A3 PCT/IB2011/050830 IB2011050830W WO2011107922A3 WO 2011107922 A3 WO2011107922 A3 WO 2011107922A3 IB 2011050830 W IB2011050830 W IB 2011050830W WO 2011107922 A3 WO2011107922 A3 WO 2011107922A3
Authority
WO
WIPO (PCT)
Prior art keywords
milnacipran
extended release
release composition
preparation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/050830
Other languages
French (fr)
Other versions
WO2011107922A2 (en
Inventor
Sumit Madan
Vinod Kumar Arora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2011107922A2 publication Critical patent/WO2011107922A2/en
Publication of WO2011107922A3 publication Critical patent/WO2011107922A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an extended release composition comprising milnacipran or its pharmaceutically acceptable salts for oral administration, and process for their preparation.
PCT/IB2011/050830 2010-03-04 2011-02-25 Extended release composition of milnacipran Ceased WO2011107922A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN481/DEL/2010 2010-03-04
IN481DE2010 2010-03-04

Publications (2)

Publication Number Publication Date
WO2011107922A2 WO2011107922A2 (en) 2011-09-09
WO2011107922A3 true WO2011107922A3 (en) 2012-04-26

Family

ID=44169177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/050830 Ceased WO2011107922A2 (en) 2010-03-04 2011-02-25 Extended release composition of milnacipran

Country Status (1)

Country Link
WO (1) WO2011107922A2 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008495A1 (en) * 1996-08-28 1998-03-05 Pierre Fabre Medicament Galenic formula with extended release of milnacipran
WO2004037190A2 (en) * 2002-10-25 2004-05-06 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004039361A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004067039A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
EP1600156A2 (en) * 2003-03-05 2005-11-30 Osmotica Corp. Combination treatment for impaired motor function in parkinson's disease
WO2005117872A2 (en) * 2004-06-04 2005-12-15 Dynogen Pharmaceuticals, Inc. Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
EP1655029A1 (en) * 2003-07-25 2006-05-10 Kyowa Hakko Kogyo Co., Ltd. Medicinal compositions
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
WO2011016057A2 (en) * 2009-08-05 2011-02-10 Lupin Limited Controlled release pharmaceutical compositions of milnacipran

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008495A1 (en) * 1996-08-28 1998-03-05 Pierre Fabre Medicament Galenic formula with extended release of milnacipran
WO2004037190A2 (en) * 2002-10-25 2004-05-06 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004039361A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004067039A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
EP1600156A2 (en) * 2003-03-05 2005-11-30 Osmotica Corp. Combination treatment for impaired motor function in parkinson's disease
EP1655029A1 (en) * 2003-07-25 2006-05-10 Kyowa Hakko Kogyo Co., Ltd. Medicinal compositions
WO2005117872A2 (en) * 2004-06-04 2005-12-15 Dynogen Pharmaceuticals, Inc. Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
WO2011016057A2 (en) * 2009-08-05 2011-02-10 Lupin Limited Controlled release pharmaceutical compositions of milnacipran

Also Published As

Publication number Publication date
WO2011107922A2 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
WO2012021715A3 (en) Stable formulations of linaclotide
WO2010092090A3 (en) Novel salts of sitagliptin
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
SG10201804817TA (en) Delayed release compositions of linaclotide
IL224288A (en) Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2011057262A3 (en) Treatment of infections with tp receptor antagonists
PL2562172T3 (en) Sphaelactone derivatives, their pharmaceutical compositions, preparation methods and uses
WO2011101863A3 (en) Extended release pharmaceutical compositions of lacosamide
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2011104652A3 (en) Veterinary compositions
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2010049449A3 (en) Novel salts of sunitinib
WO2011079193A3 (en) Preparation of bendamustine and its salts
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
HK1208222A1 (en) Modified release formulations for oprozomib
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
MX2012001691A (en) Orally disintegrating compositions of linaclotide.
WO2012074830A3 (en) Modified release tranexamic acid formulation
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11713059

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11713059

Country of ref document: EP

Kind code of ref document: A2